军事知识服务平台
2022—2023年浙江省血液肿瘤患儿化疗后血清破伤风抗体水平调查
Survey on serum tetanus antibody levels in children with hematological malignancies post-chemotherapy in Zhejiang Province from 2022 to 2023
摘要 动态监测血液肿瘤患儿化疗前后血清破伤风抗体水平变化,评估化疗后再次接种含破伤风成分疫苗(TTCVs)的必要性。纳入2022年1月至2023年12月在浙江大学医学院附属儿童医院住院治疗的293例15岁以下血液肿瘤患儿为病例组,匹配293名同年龄社区健康儿童为对照组,检测病例组患儿化疗前、化疗后1个月及对照组破伤风IgG抗体水平,采用 χ2检验和 t检验比较各组间抗体阳性率及滴度水平差异。2组男女性别比分别为1.24∶1和1.20∶1;年龄为(6.66±3.66)岁和(6.94±3.73)岁。病例组化疗后1个月破伤风IgG抗体阳性率(70.99%)显著低于化疗前(84.64%)( χ2=73.10, P<0.001)及对照组(84.98%)( χ2=16.72, P<0.001);化疗后破伤风IgG抗体几何平均浓度[(0.73±0.11)IU/ml]显著低于化疗前[(1.22±0.17)IU/ml]( t=4.61, P<0.001)及对照组[(1.06±0.06)IU/ml]( t=1.98, P=0.048)。综上,肿瘤患儿化疗后1个月破伤风IgG抗体水平较化疗前下降,且低于健康人群。
Abstract:
To dynamically monitor changes in the levels of serum tetanus antibody in children with hematological malignancies before and after chemotherapy, and to evaluate the necessity of re-vaccination with tetanus-toxoid-containing vaccine (TTCVs) post-chemotherapy. A total of 293 children under 15 years old with hematological malignancies hospitalized in the Children′s Hospital affiliated with the School of Medicine at Zhejiang University from January 2022 to December 2023 were included as the case group, matched with 293 community-based healthy children of the same age as the control group. The level of tetanus IgG antibody was measured in the case group pre-chemotherapy and 1 month post-chemotherapy, as well as in the control group. The χ2 test and t-test were used to compare the differences in the positive rate and geometric mean concentration (GMC) of tetanus IgG antibody among groups. The male-to-female ratios were 1.24∶1 and 1.20∶1, and the mean ages were (6.66±3.66) years and (6.94±3.73) years for the two groups, respectively. The positive rate of tetanus IgG antibody post-chemotherapy (70.99%) was significantly lower than that pre-chemotherapy (84.64%) ( χ2=73.10, P<0.001), and also significantly lower than that in the control group (84.98%) ( χ2=16.72, P<0.001). The GMC of tetanus IgG antibody post-chemotherapy (0.73±0.11 IU/ml) was significantly lower than that pre-chemotherapy (1.22±0.17 IU/ml) ( t=4.61, P<0.001). It was also significantly lower than that of the control group (1.06±0.06 IU/ml) ( t=1.98, P=0.048). In conclusion, the level of tetanus IgG antibody in children with tumors 1 month post-chemotherapy decreases compared with that pre-chemotherapy and is lower than that in the healthy population.
刊 名 中华预防医学杂志 ISTICPKU
年,卷(期): 2026, 60(10)
在线出版日期: 2026年10月6日